Full Text Journal Articles by
Author Siraj M Ali

Advertisement

Find full text journal articles






Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer.

Stacey M Stein, Jeremy Snider, Siraj M Ali, Rebecca A Miksad, Brian M Alexander, Emily Castellanos, Alexa B Schrock, Russell Madison, Akshay Swaminathan, Jeffrey M Venstrom, Margaret McCusker,

<b>Aim:</b> To assess concordance between HER2 status measured by traditional methods and <i>ERBB2</i> amplification measured by next-generation sequencing and its association with first-line trastuzumab clinical benefit in patients with advanced esophagogastric cancer. <b>Methods:</b> Retrospective analysis of HER2/<i>ERBB2</i> concordance using a deidentified USA-based clinicogenomic database. Clinical outcomes were assessed for patients ... Read more >>

Future Oncol (Future oncology (London, England))
[2021, :]

Cited: 0 times

View full text PDF listing >>



Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas.

Simona Corso, Filippo Pietrantonio, Maria Apicella, Cristina Migliore, Daniela Conticelli, Annalisa Petrelli, Laura D'Errico, Stefania Durando, Daniel Moya-Rull, Sara E Bellomo, Stefano Ughetto, Maurizio Degiuli, Rossella Reddavid, Uberto Fumagalli, Stefano De Pascale, Giovanni Sgroi, Emanuele Rausa, Gian Luca Baiocchi, Sarah Molfino, Giovanni De Manzoni, Maria Bencivenga, Salvatore Siena, Andrea Sartore-Bianchi, Federica Morano, Salvatore Corallo, Michele Prisciandaro, Maria Di Bartolomeo, Annunziata Gloghini, Silvia Marsoni, Antonino Sottile, Anna Sapino, Caterina Marchiò, Asa Dahle-Smith, Zosia Miedzybrodzka, Jessica Lee, Siraj M Ali, Jeffrey S Ross, Brian M Alexander, Vincent A Miller, Russell Petty, Alexa B Schrock, Silvia Giordano,

<h4>Purpose</h4>Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomized clinical trials failed to show a significant survival benefit in molecularly unselected patients with advanced gastroesophageal adenocarcinoma treated with anti-EGFR agents.<h4>Experimental design</h4>We ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(11):3126-3140]

Cited: 1 time

View full text PDF listing >>



Advertisement

Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics.

Denis L Jardim, Sherri Z Millis, Jeffrey S Ross, Michelle Sue-Ann Woo, Siraj M Ali, Razelle Kurzrock,

The cyclin pathway may confer resistance to standard treatments but also offer novel therapeutic opportunities in prostate cancer. Herein, we analyzed prostate cancer samples (majority metastatic) using comprehensive genomic profiling performed by next-generation sequencing (315 genes, >500× coverage) for alterations in activating and sensitizing cyclin genes (CDK4 amplification, CDK6 amplification, ... Read more >>

Oncologist (The oncologist)
[2021, 26(4):e715-e718]

Cited: 0 times

View full text PDF listing >>



Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.

Marco Bandini, Jeffrey S Ross, Daniele Raggi, Andrea Gallina, Maurizio Colecchia, Roberta Lucianò, Patrizia Giannatempo, Elena Farè, Filippo Pederzoli, Marco Bianchi, Renzo Colombo, Giorgio Gandaglia, Nicola Fossati, Laura Marandino, Umberto Capitanio, Federico Deho', Siraj M Ali, Russell Madison, Jon H Chung, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Andrea Necchi,

<h4>Background</h4>In the PURE-01 study (NCT02736266), we aimed to evaluate the ability to predict the pathologic complete response (pT0N0) after pembrolizumab by using clinical and tumor biomarkers.<h4>Methods</h4>In an open-label, single-arm, phase 2 study, 3 courses of 200 mg pembrolizumab preceding radical cystectomy were administered in patients with T2-4aN0M0 muscle-invasive bladder cancer. The ... Read more >>

J Natl Cancer Inst (Journal of the National Cancer Institute)
[2021, 113(1):48-53]

Cited: 2 times

View full text PDF listing >>



Targetable gene fusions and aberrations in genitourinary oncology.

Filippo Pederzoli, Marco Bandini, Laura Marandino, Siraj M Ali, Russell Madison, Jon Chung, Jeffrey S Ross, Andrea Necchi,

Gene fusions result from either structural chromosomal rearrangement or aberrations caused by splicing or transcriptional readthrough. The precise and distinctive presence of fusion genes in neoplastic tissues and their involvement in multiple pathways central to cancer development, growth and survival make them promising targets for personalized therapy. In genitourinary malignancies, ... Read more >>

Nat Rev Urol (Nature reviews. Urology)
[2020, 17(11):613-625]

Cited: 8 times

View full text PDF listing >>



Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.

Aparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, Le Huang, Shuang Liu, Kenneth Hess, Maria Cabanillas, Mimi I Hu, Naifa L Busaidy, Steven I Sherman, Ramona Dadu, Elizabeth G Grubbs, Siraj M Ali, Jessica Lee, Yasir Y Elamin, George R Simon, George R Blumenschein, Vassiliki A Papadimitrakopoulou, David Hong, Funda Meric-Bernstam, John Heymach, Vivek Subbiah,

<h4>Purpose</h4>The receptor tyrosine kinase rearranged during transfection (RET) can be oncogenically activated by gene fusions or point mutations. Multikinase inhibitors such as cabozantinib, lenvatinib and vandetanib have demonstrated activity in RET-dependent malignancies, and selective RET inhibitors (Selpercatinib and Pralsetinib) are in clinical trials. However, the responsiveness of RET-dependent malignancies to ... Read more >>

ESMO Open (ESMO open)
[2020, 5(5):e000799]

Cited: 5 times

View full text PDF listing >>



Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.

Andrew Rankin, Adrienne Johnson, Alison Roos, Geoffrey Kannan, Jeffrey Knipstein, Nicholas Britt, Mark Rosenzweig, James Haberberger, Dean Pavlick, Eric Severson, Jo-Anne Vergilio, Rachel Squillace, Rachel Erlich, Pratheesh Sathyan, Stuart Cramer, David Kram, Jeffrey Ross, Vince Miller, Prasanth Reddy, Brian Alexander, Siraj M Ali, Shakti Ramkissoon,

RAF family protein kinases signal through the MAPK pathway to orchestrate cellular proliferation, survival, and transformation. Identifying BRAF alterations in pediatric cancers is critically important as therapeutic agents targeting BRAF or MEK may be incorporated into the clinical management of these patients. In this study, we performed comprehensive genomic profiling ... Read more >>

Oncologist (The oncologist)
[2021, 26(1):e153-e163]

Cited: 1 time

View full text PDF listing >>



Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA.

Saranya Akumalla, Russell Madison, Douglas I Lin, Alexa B Schrock, Evgeny Yakirevich, Mark Rosenzweig, Arjun V Balar, Garrett M Frampton, Claire Edgerly, Rachel L Erlich, Vincent A Miller, Shridar Ganesan, Jeffrey S Ross, Siraj M Ali,

<h4>Purpose</h4>Perivascular epithelioid cell tumor (PEComa) is a rare mesenchymal soft tissue neoplasm often linked to mTOR pathway activation via TSC2 mutation. We analyzed a series of 31 consecutive metastatic PEComa (mPEComa) cases using a combined DNA/RNA hybrid capture-based comprehensive genomic profiling (CGP) assay to assess the genomic landscape of mPEComa.<h4>Patients ... Read more >>

Oncology (Oncology)
[2020, 98(12):905-912]

Cited: 0 times

View full text PDF listing >>



Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions.

Denis L Jardim, Sherri Z Millis, Jeffrey S Ross, Michelle Sue-Ann Woo, Siraj M Ali, Razelle Kurzrock,

<h4>Background</h4>We describe the landscape of cyclin and interactive gene pathway alterations in 190,247 solid tumors.<h4>Methods</h4>Using comprehensive genomic profiling (315 genes, >500× coverage), samples were analyzed for alterations in activating/sensitizing cyclin genes (CDK4 amplification, CDK6 amplification, CCND1, CCND2, CCND3, CDKN2B [loss], CDKN2A [loss], SMARCB1), hormone genes (estrogen receptor 1 [ESR1], androgen ... Read more >>

Oncologist (The oncologist)
[2021, 26(1):e78-e89]

Cited: 2 times

View full text PDF listing >>



Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.

Andrea Necchi, Russell Madison, Sumanta K Pal, Jeffrey S Ross, Neeraj Agarwal, Guru Sonpavde, Monika Joshi, Ming Yin, Vincent A Miller, Petros Grivas, Jon H Chung, Siraj M Ali,

<h4>Background</h4>Characterization of the different genomic alterations (GAs) in urothelial carcinoma (UC), by site of origin, may identify contrasting therapeutic opportunities and inform distinct putative pathogenetic mechanisms.<h4>Objective</h4>To describe the genomic landscape of UC based on the anatomic site of the primary tumor.<h4>Design, setting, and participants</h4>In total, 479 upper tract UC (UTUC) ... Read more >>

Eur Urol Focus (European urology focus)
[2020, :]

Cited: 4 times

View full text PDF listing >>



Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.

Russell Madison, Alexa B Schrock, Emily Castellanos, Jeffrey P Gregg, Jeremy Snider, Siraj M Ali, Vincent A Miller, Gaurav Singal, Brian M Alexander, Jeffrey M Venstrom, Jon H Chung,

<h4>Objectives</h4>Liquid biopsy and comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) are increasingly used for detection of targetable genomic alterations (GA) in non-small cell lung cancer (NSCLC). To examine the clinical outcomes for patients following CGP using liquid biopsy versus tissue biopsy, receipt of matched targeted therapy post-CGP and ... Read more >>

Lung Cancer (Lung cancer (Amsterdam, Netherlands))
[2020, 148:69-78]

Cited: 3 times

View full text PDF listing >>



Recurrent secondary genomic alterations in desmoplastic small round cell tumors.

Warren A Chow, Jiing-Kuan Yee, Walter Tsark, Xiwei Wu, Hanjun Qin, Min Guan, Jeffrey S Ross, Siraj M Ali, Sherri Z Millis,

BACKGROUND:Desmoplastic small round cell tumor (DSRCT) is a rare, highly aggressive, translocation-associated soft-tissue sarcoma that primarily affects children, adolescents, and young adults, with a striking male predominance. It is characterized by t(11;22) generating a novel EWSR1-WT1 fusion gene. Secondary genomic alterations are rarely described. METHODS:Tumor tissue from 83 DSRCT patients ... Read more >>

BMC Med Genet (BMC medical genetics)
[2020, 21(1):101]

Cited: 3 times

View full text PDF listing >>



Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.

Ethan S Sokol, Dean Pavlick, Hossein Khiabanian, Garrett M Frampton, Jeffrey S Ross, Jeffrey P Gregg, Primo N Lara, Steffi Oesterreich, Neeraj Agarwal, Andrea Necchi, Vincent A Miller, Brian Alexander, Siraj M Ali, Shridar Ganesan, Jon H Chung,

<h4>Purpose</h4>BRCA1 or BRCA2 loss of function results in homologous recombination deficiency (HRD), which is targetable by poly (ADP-ribose) polymerase (PARP) inhibitors and other DNA-damaging agents. In cancers associated with germline <i>BRCA1/2</i> alterations (<i>BRCA1/2</i>-associated cancers: breast, ovarian, pancreatic, prostate), <i>BRCA1/2</i> alterations result in HRD and are biomarkers for PARP inhibitor use. ... Read more >>

JCO Precis Oncol (JCO precision oncology)
[2020, 4:442-465]

Cited: 8 times

View full text PDF listing >>



Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors.

Alexa B Schrock, Russell Madison, Mark Rosenzweig, Justin M Allen, Rachel L Erlich, Siao-Yi Wang, Tarek Chidiac, Vodur Suresh Reddy, Jonathan W Riess, Ahmet Ersin Yassa, Abdur Shakir, Vincent A Miller, Brian M Alexander, Jeffrey Venstrom, Kimberly McGregor, Siraj M Ali,

Background:ALK fusions are targetable drivers in non-small-cell lung cancer (NSCLC). However, patients with NSCLC harboring ALK rearrangements without a fusion partner identified in DNA have also been shown to respond to ALK inhibitors. We aimed to characterize complex ALK variants that may predict sensitivity to multiple approved ALK inhibitors. Methods:Comprehensive ... Read more >>

Lung Cancer (Auckl) (Lung Cancer (Auckland, N.Z.))
[2020, 11:33-39]

Cited: 0 times

View full text PDF listing >>



Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.

Douglas I Lin, Amanda Hemmerich, Claire Edgerly, Daniel Duncan, Eric A Severson, Richard S P Huang, Shakti H Ramkissoon, Yamicia D Connor, Meghan Shea, Jonathan L Hecht, Siraj M Ali, Jo-Anne Vergilio, Jeffrey S Ross, Julia A Elvin,

OBJECTIVE:Genomic alterations of BCOR via ZC3H7B-BCOR fusion or BCOR internal tandem duplication (ITD) define a subset of endometrial stromal sarcoma (ESS). The goals of this study were to: 1) determine the molecular landscape of BCOR-rearranged ESS, 2) to identify novel BCOR fusion gene partners in ESS and their associated clinicopathological ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2020, 157(2):357-366]

Cited: 8 times

View full text PDF listing >>



Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions.

Russell W Madison, Sumati V Gupta, Yasir Y Elamin, Douglas I Lin, Sumanta K Pal, Andrea Necchi, Vincent A Miller, Jeffrey S Ross, Jon H Chung, Brian M Alexander, Alexa B Schrock, John V Heymach, Prasanth Reddy, Siraj M Ali,

OBJECTIVE:To review the genomic landscape of advanced urothelial carcinoma (UC) to assess the frequencies of EGFR and ERBB2 (HER2) alterations. MATERIALS AND METHODS:Tumour specimens from 3753 patients with advanced UC were assayed with hybrid capture-based comprehensive genomic profiling of 180-395 genes. Tumour mutational burden (TMB) was assessed on 0.8 or ... Read more >>

BJU Int (BJU international)
[2020, 125(5):739-746]

Cited: 2 times

View full text PDF listing >>



Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.

Marco Bandini, Filippo Pederzoli, Russell Madison, Alberto Briganti, Jeffrey S Ross, Günter Niegisch, Evan Y Yu, Aristotelis Bamias, Neeraj Agarwal, Srikala S Sridhar, Jonathan E Rosenberg, Joaquim Bellmunt, Sumanta Kumar Pal, Matthew D Galsky, Roberta Lucianò, Andrea Gallina, Andrea Salonia, Francesco Montorsi, Siraj M Ali, Jon H Chung, Andrea Necchi,

<h4>Background</h4>Nonurothelial carcinoma (UC) malignancies have traditionally been considered to have a more aggressive clinical course, and little is known about their response to neoadjuvant therapy. We examined the effect of neoadjuvant chemotherapy (NAC) on a large population of patients with bladder cancer (BCa) with different histologic variants (HVs).<h4>Patients and methods</h4>We ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2020, 18(5):e543-e556]

Cited: 2 times

View full text PDF listing >>



Clinicopathologic Characteristics of BRG1-Deficient NSCLC.

Ibiayi Dagogo-Jack, Alexa B Schrock, Marina Kem, Nicholas Jessop, Jessica Lee, Siraj M Ali, Jeffrey S Ross, Jochen K Lennerz, Alice T Shaw, Mari Mino-Kenudson,

<h4>Introduction</h4>Ten percent of NSCLCs harbor mutations in SMARCA4, the gene encoding the SWItch/Sucrose Non-Fermentable ATPase BRG1. In preclinical models, BRG1 inactivation increases tumor aggressiveness but enhances sensitivity to drugs that target oxidative phosphorylation and inhibit SMARCA2, EZH2, CDK4, or CDK6. To facilitate translation of preclinical findings into clinical studies exploiting ... Read more >>

J Thorac Oncol (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer)
[2020, 15(5):766-776]

Cited: 14 times

View full text PDF listing >>



Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.

Andrea Necchi, Russell Madison, Daniele Raggi, Joseph M Jacob, Gennady Bratslavsky, Oleg Shapiro, Julia A Elvin, Jo-Anne Vergilio, Jonathan K Killian, Nhu Ngo, Shakti Ramkissoon, Eric Severson, Amanda C Hemmerich, Richard Huang, Siraj M Ali, Jon H Chung, Prasanth Reddy, Vincent A Miller, Alexa B Schrock, Laurie M Gay, Brian M Alexander, Petros Grivas, Jeffrey S Ross,

<h4>Background</h4>In patients with rare histologies of bladder cancer, including adenocarcinoma of the bladder (ACB) and squamous-cell carcinoma (SCC), there are limited standard therapy options, defining an unmet medical need.<h4>Objective</h4>In this comparative comprehensive genomic profiling (CGP) study, genomic alterations (GAs), and immuno-oncology (IO) biomarkers have been analyzed.<h4>Design, setting, and participants</h4>Within the ... Read more >>

Eur Urol (European urology)
[2020, 77(4):548-556]

Cited: 10 times

View full text PDF listing >>



Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.

Andrea Necchi, Marco Bandini, Giuseppina Calareso, Daniele Raggi, Filippo Pederzoli, Elena Farè, Maurizio Colecchia, Laura Marandino, Marco Bianchi, Andrea Gallina, Renzo Colombo, Nicola Fossati, Giorgio Gandaglia, Umberto Capitanio, Federico Dehò, Patrizia Giannatempo, Roberta Lucianò, Andrea Salonia, Russell Madison, Siraj M Ali, Jon H Chung, Jeffrey S Ross, Alberto Briganti, Francesco Montorsi, Francesco De Cobelli, Antonella Messina,

<h4>Background</h4>In the PURE-01 study, pembrolizumab was given preoperatively before radical cystectomy in clinical T2-4aN0M0 patients. An accurate clinical response assessment may be useful for developing new perioperative strategies in these patients.<h4>Objective</h4>To evaluate the association between bladder multiparametric magnetic resonance imaging (mpMRI) findings after pembrolizumab and the pathological complete response (CR; ... Read more >>

Eur Urol (European urology)
[2020, 77(5):636-643]

Cited: 8 times

View full text PDF listing >>



Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.

Andrea Necchi, Daniele Raggi, Andrea Gallina, Russell Madison, Maurizio Colecchia, Roberta Lucianò, Rodolfo Montironi, Patrizia Giannatempo, Elena Farè, Filippo Pederzoli, Marco Bandini, Marco Bianchi, Renzo Colombo, Giorgio Gandaglia, Nicola Fossati, Laura Marandino, Umberto Capitanio, Federico Dehò, Siraj M Ali, Jon H Chung, Jeffrey S Ross, Andrea Salonia, Alberto Briganti, Francesco Montorsi,

<h4>Background</h4>Patients with predominant variant histology (VH) of bladder tumors, defined as involving >50 % of the tumor specimens, are typically excluded from clinical trials, and for these patients, the efficacy of standard chemotherapy is limited.<h4>Objective</h4>To evaluate the activity of preoperative pembrolizumab in patients with muscle-invasive bladder carcinoma (MIBC) and VH, ... Read more >>

Eur Urol (European urology)
[2020, 77(4):439-446]

Cited: 23 times

View full text PDF listing >>



Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling.

Nazli Dizman, Meghan Salgia, Siraj M Ali, Huiqing Wu, Leonidas Arvanitis, Jon H Chung, Sumanta K Pal,

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2020, 18(3):e289-e292]

Cited: 0 times

View full text PDF listing >>



The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.

Umut Disel, Russell Madison, Kumar Abhishek, Jon H Chung, Sally E Trabucco, Asli O Matos, Garrett M Frampton, Lee A Albacker, Venkataprasanth Reddy, Nuri Karadurmus, Adam Benson, Jennifer Webster, Semra Paydas, Ruben Cabanillas, Chaitali Nangia, M A Ozturk, Sherri Z Millis, Sumanta K Pal, Breelyn Wilky, Ethan S Sokol, Laurie M Gay, Salil Soman, Shridar Ganesan, Katherine Janeway, Phil J Stephens, Viola W Zhu, Sai-Hong Ignatius Ou, Christine M Lovly, Mrinal Gounder, Alexa B Schrock, Jeffrey S Ross, Vincent A Miller, Samuel J Klempner, Siraj M Ali,

<h4>Purpose</h4>Amplifications of receptor tyrosine kinases (RTKS) are therapeutic targets in multiple tumor types (e.g. HER2 in breast cancer), and amplification of the chromosome 4 segment harboring the three RTKs KIT, PDGFRA, and KDR (4q12amp) may be similarly targetable. The presence of 4q12amp has been sporadically reported in small tumor specific ... Read more >>

Oncologist (The oncologist)
[2020, 25(1):e39-e47]

Cited: 3 times

View full text PDF listing >>



Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib.

Mohammed Hassan, Erin Butler, Raphael Wilson, Angshumoy Roy, Yanbin Zheng, Priscilla Liem, Dinesh Rakheja, Dean Pavlick, Lauren L Young, Mark Rosenzweig, Rachel Erlich, Siraj M Ali, Patrick J Leavey, D Williams Parsons, Stephen X Skapek, Theodore W Laetsch,

Infantile myofibromatosis (IM) is an aggressive neoplasm composed of myofibroblast-like cells in children. Although typically localized, it can also present as multifocal disease, which represents a challenge for effective treatment. IM has previously been linked to activating somatic and germline point mutations in the PDGFRβ tyrosine kinase encoded by the ... Read more >>

Cold Spring Harb Mol Case Stud (Cold Spring Harbor molecular case studies)
[2019, 5(5):]

Cited: 1 time

View full text PDF listing >>



Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.

Gerald Li, Dean Pavlick, Jon H Chung, Todd Bauer, Bradford A Tan, Julio Peguero, Patrick Ward, Andre Kallab, Jose Bufill, Anthony Hoffman, Ahad Sadiq, Jeff Edenfield, Jie He, Matthew Cooke, Jason Hughes, Brady Forcier, Michelle Nahas, Phil Stephens, Siraj M Ali, Alexa B Schrock, Jeffrey S Ross, Vincent A Miller, Jeffrey P Gregg,

<h4>Background</h4>Liquid biopsy offers the ability to non-invasively analyze the genome of a tumor through circulating tumor DNA (ctDNA) to identify targetable and prognostic genomic alterations. Few studies have rigorously analyzed ctDNA results and determined the fidelity with which they recapitulate the genomics of a sequenced tissue sample obtained from the ... Read more >>

J Gastrointest Oncol (Journal of gastrointestinal oncology)
[2019, 10(5):831-840]

Cited: 8 times

View full text PDF listing >>



Advertisement


Disclaimer

1.1863 s